Decreased Human T Lymphotropic Virus Type I (HTLV-I) Provirus Load and Alteration in T Cell Phenotype after Interferon-α Therapy for HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis

Journal of Infectious Diseases

Volumn 189, Issue 1, 2004, Pages 29-40

  Saito, Mineki ^a,b,e   Nakagawa, Masanori ^a,f   Kaseda, Shun ^a   Matsuzaki, Toshio ^a   Jonosono, Manabu ^a,g   Eiraku, Nobutaka ^a   Kubota, Ryuji ^a   Takenouchi, Norihiro ^a,c   Nagai, Masahiro ^a,h   Furukawa, Yoshitaka ^d   Usuku, Koichiro ^b   Izumo, Shuji ^c   Osame, Mitsuhiro ^a  

^a Dept of Neurology and Geriatrics ^*  (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^e Japan Found for Aging and Health   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g Okinawa Prefectural Chubu Hospital   (Japan)

^h EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PREDNISOLONE;

ADULT; AGED; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GENE FREQUENCY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOMODULATION; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIGENS, CD27; ANTIGENS, CD45; ANTIGENS, CD8; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; LYMPHOCYTE COUNT; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; PORE FORMING CYTOTOXIC PROTEINS; PROVIRUSES; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 9144261576     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/380101     Document Type: Article

References (49)

1. Poiesz BJ, Ruscetti RW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-9.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79:2031-5.
3. Hinuma Y, Nagata K, Misaka M, et al. Adult T cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78:6476-80.
4. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in disease. Proc Natl Acad Sci USA 1984; 81:2534-7.
5. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet 1985; 2:407-10.
6. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity [letter]. Lancet 1986; 1:1031-2.
7. Izumo S, Umehara F, Osame M. HTLV-I-associated myelopathy. Neuropathology 2000; 20 (Suppl):S65-8.
8. Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons in-fected with HTLV-I. J Acquir Immune Defic Syndr 1990; 3:1096-101.
9. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I provirus load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high provirus load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-93.
10. Mori M, Kinoshita K, Ban N, Yamada Y, Shiku H. Activated T-lymphocytes with polyclonal gammopathy in patients with human T-lymphotropic virus type !-associated myelopathy. Ann Neurol 1988; 24:280-2.
11. Ijichi S, Eiraku N, Osame M, et al. Activated T lymphocytes in cere-brospinal fluid of patients with HTLV-I-associated myelopathy (HAM/ TSP). J Neuroimmunol 1989; 25:251-4.
12. Itoyama Y, Minato S, Kira J, et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 1988; 38:1302-7.
13. Jacobson S, Zaninovic V, Mora C, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol 1988; 23(Suppl):S196-200.
14. Eiraku N, Ijichi S, Yashiki S, Osame M, Sonoda S. Cell surface phenotype of in vitro proliferating lymphocytes in HTLV-I-associatedmyelopathy (HAM/TSP). J Neuroimmunol 1992; 37:223-8.
15. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S. High human T cell lymphotropic virus type 1 (HTLV-I)-specific pre-cursor cytotoxic T lymphocyte frequencies in patients with HTLV-Iassociated neurological disease. J Exp Med 1993; 177:1567-73.
16. Parker CE, Daenke SD, Nightingale S, Bangham CRM. Activated HTLV-I-specific cytotoxic T cells are found in healthy seropositives as well as patients with tropical spastic paraparesis. Virology 1992; 188:628-36.
17. + T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/ TSP patients. Proc Natl Acad Sci USA 1998; 95:7568-73.
18. + T cells in cerebrospinal fluid from patients with HAM/ TSP. Ann Neurol 2001; 50:807-12.
19. + lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 1998; 161:482-8.
20. Jeffery KJM, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999:96:3848-53.
21. Osame M, Matsumoto M, Usuku K, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells. Ann Neurol 1987; 21: 117-22.
22. Osame M, Igata A, Matsumoto M, et al. HTLV-I-associatedmyelopathy (HAM): treatment trials, retrospective survey, and clinical and laboratory findings. Hematol Rev 1990; 3:271-84.
23. Matsuo H, Nakamura T, Tsujihata M, et al. Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet 1988; 2:1109-13.
24. Nakamura T, Shibayama K, Nagasato K, Matsuo H, Tsujihata M, Nagataki S. The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy. Jpn J Med 1990; 29:362-7.
25. Kuroda Y, Kurohara K, Fujiyama F, et al. Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand 1992; 86: 82-6.
26. Yamasaki K, Kira J, Koyanagi Y, et al. Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci 1997; 147:135-44.
27. Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, con-trolled trial. Neurology 1996; 46:1016-21.
28. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003; 9:29-35.
29. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA, ed. Human retrovirology: HTLV. New York: Raven Press, 1990:191-7.
30. Altman JD, Moss PH, Goulder PR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6.
31. Nomoto M, Utatsu Y, Soejima Y, Osame M. Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-!-associated myelopathy/ tropical spastic paraparesis. Neurology 1991; 41:457.
32. + T cells. J Exp Med 1997; 186:1407-18.
33. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998; 9:1-11.
34. Mackay CR. Chemokine receptors and T cell chemotaxis. J Exp Med 1996; 184:799-802.
35. Ochi H, Wu XM, Osoegawa M, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperlgEaemic myelitis. J Neuroimmunol 2001; 119:297-305.
36. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-8.
37. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12:511-6.
38. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-30.
39. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370:650-2.
40. Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 1995; 16:202-6.
41. Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunol Today 1995; 16:194-201.
42. Griffiths GM, Mueller C. Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. Immunol Today 1991; 12:415-9.
43. Hanon E, Hall S, Taylor GP, et al. Abundant tax protein expression in CD4T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000; 95:1386-92.
44. Yasunaga JI, Sakai T, Nosaka K, et al. Impaired production of naïve T lymphocytes in human T-cell leukemia virus type-I infected individuals: its implications in the immunodefkient state. Blood 2001; 97:3177-83.
45. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S. Increased activated human T cell Iymphotropic virus type 1 (HTLV-I) Taxi 1-19-specifk memory and effector CDS+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 2001; 183:197-205.
46. Hanon E, Goon P, Taylor GP, et al. High production of interferon gamma but not interIeukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. Blood 2001; 98:721-6.
47. + T cells are increased in multiple sclerosis and their ligands MIP-lalpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96:6873-8.
48. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985:37:85-8.
49. Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol 1997; 107:359-63.